Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort

Jones, D. E. J.; Bhala, N.; Burt, J.; Goldblatt, J.; Prince, M.; Newton, J. L.
April 2006
Gut;Apr2006, Vol. 55 Issue 4, p536
Academic Journal
Background and aims: Fatigue is the commonest symptom described by patients in most populations with the autoimmune liver disease primary biliary cirrhosis (PBC), and appears to be unrelated to liver disease severity. At present, it is unclear how the fatigue experienced by patients (only characterised to date in cross section studies) evolves over time. In this study, we set out to address how fatigue had changed over four years of follow up in a geographically defined cohort of PBC patients who participated in an earlier cross sectional study of fatigue impact. Methods: Participants in the original 2000 study who were still alive in 2004 were asked to complete the same fatigue assessment tool (fatigue impact score, FIS). In those who had died between 2000 and 2004, medical notes, death certificates, and primary care records were reviewed. Results: A total of 108 of the original cohort of 136 patients were alive at the time of the follow up study, 99 of whom (92%) participated in the follow up study. With the exception of four patients who underwent transplantation between 2000 and 2004, all of whom showed significant improvement in fatigue severity as assessed by FIS, fatigue severity was unchanged over four years of follow up. Among the 28 patients who died during the follow up period, survival was significantly lower in patients who were fatigued at the 2000 baseline (FIS above the median for the whole PBC population (40/160); log rank test, p = 0.006 v non-fatigued patients at baseline). Increased fatigue severity was independently associated with decreased survival on multivariate analysis. Fatigued PBC subjects were significantly more likely to have suffered a cardiac death than non-fatigued patients. Conclusions: The fatigue phenotype appears to be highly stable in PBC. The presence of fatigue in PBC is independently associated with a significantly increased risk of death in general, and cardiac death in particular. Factors underpinning fatigue in PBC, and the mechanisms whereby fatigue is associated with increased mortality, warrant further study.


Related Articles

  • Complications of Biliary Atresia in a 27-Year-Old Male Patient. Lugito, Nata Pratama Hardjo; Tyasto, I Gede Resmino; Laksmi, Purwita Wijaya // Indonesian Journal of Gastroenterology, Hepatology & Digestive E;Apr2014, Vol. 14 Issue 1, p44 

    Biliary atresia (BA) is a disease of the extrahepatic biliary tree that presents with biliary obstruction in the neonatal period, which is caused by fibro-obliterative process. Kasai procedure, a hepatoportoenterostomy (HPE) as an attempt to restore bile flow from the liver to the proximal small...

  • Mitochondrial Antibody in Primary Biliary Cirrhosis and Other Diseases. Klatskin, Gerald; Kantor, Fred S. // Annals of Internal Medicine;Oct72, Vol. 77 Issue 4, p533 

    Presents a study that investigated mitochondrial antibody in the serum of patients with primary biliary cirrhosis and other liver diseases. Assessment of the incidence of mitochondrial antibody; Analysis of patients with chronic active hepatitis; Examination of patients with cryptogenic cirrhosis.

  • Ischemia-Reperfusion Injury and Ischemic-Type Biliary Lesions following Liver Transplantation. Cursio, Raffaele; Gugenheim, Jean // Journal of Transplantation;2012, p1 

    Ischemia-reperfusion (I-R) injury after liver transplantation (LT) induces intra- and/or extrahepatic nonanastomotic ischemictype biliary lesions (ITBLs). Subsequent bile duct stricture is a significant cause of morbidity and even mortality in patients who underwent LT. Although the pathogenesis...

  • Retrospective survey on laparoscopic cholecystectomy in the cirrhotic patient. CAPPELLANI, A.; CACOPARDO, B.; ZANGHÌ, A.; CAVALLARO, A.; DI VITA, M.; ALFANO, G.; LO MENZO, E. // European Review for Medical & Pharmacological Sciences;Jul/Aug2008, Vol. 12 Issue 4, p257 

    Cholelitiasis is a common disease in patients with liver cirrhosis, mainly due to intravascular haemolysis and functional alterations of the gallbladder. In Child A and B cirrhotics laparoscopic cholecystectomy (LC) demonstrated the same advantages and safety as in the non cirrhotic patients. On...

  • Treatment of primary biliary cirrhosis. Babbs, C.; Smith, A.; Warnes, T.W. // British Medical Journal (Clinical Research Edition);12/5/1987, Vol. 295 Issue 6611, p1486 

    Focuses on the treatment of biliary cirrhosis. Use of corticosteroids and colchicine; Drug trials to determine potency; Discussions and suggestions for future studies on drugs in the treatment of primary biliary cirrhosis.

  • Small Bowel Motility in Primary Biliary Cirrhosis. Madrid, A. M.; Brahm, J.; Antezana, C.; González-Koch, A.; DeOlippi, Cl.; Pimentel, C.; Oksenberg, D.; Defilippi, C. // American Journal of Gastroenterology;Dec1998, Vol. 93 Issue 12, p2436 

    Objective: Previous studies have shown small bowel motor activity abnormalities in patients with liver cirrhosis of different etiologies, but motility has not been studied in patients with primary biliary cirrhosis. Our aim was to investigate proximal small bowel motility in these patients....

  • Serum Transaminase Activity in Liver and Biliary Tract Diseases. Percic, Vinko; Stojšic, Stevan; Hegedis, Tibor; Ostrogonac, Marko // American Journal of Gastroenterology;May1966, Vol. 45 Issue 5, p348 

    Provides information on a 1966 study conducted by Marko Ostrogonac et al, regarding the serum glutamine-pyruvic transaminase (SGPT) and serum glutamine-oxalacetic transaminase (SGOT) activity and their comparison with other routine tests of hepatic function in patients with hepatobiliary...

  • Pilot Study of Low Dose Oral Methotrexate Treatment for Primary Biliary Cirrhosis. Bergasa, Nora Valeria; Jones, E. Anthony; Kleiner, David E.; Rabin, Lionel; Yoon Park; Wells, Mary C.; Hoofnagle, Jay H. // American Journal of Gastroenterology;Feb1996, Vol. 91 Issue 2, p295 

    Objective: To assess the efficacy of low doses of oral methotrexate as therapy for primary biliary cirrhosis. Methods: Ten symptomatic patients with this disease were treated with methotrexate at a dose of 15 mg/wk in an open label trial. Results: Eight patients completed 1 yr of treatment and...

  • Patients with m2 antibodies: what diagnosis and follow-up are they given? Byrne, E. A. L.; Katbamna, R.; Scott, C.; Blanshard, C.; Marley, R.; Coppack, S. W.; Foster, G. R. // Gut;Jun2010, Vol. 59 Issue 6, p21 

    The article probes into the diagnosis and follow-up methods used for patients with M2 antibodies. Presently, diagnosis is conducted based on the M2 substrate of anti-mitochondrial antibody (AMA) found in the sera and liver function tests. Diagnosis of primary biliary cirrhosis (PBC) is...


Read the Article


Sign out of this library

Other Topics